Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MRNA VACCINES AGAINST INFLUENZA IN ADULTS 18 YEARS OF AGE AND OLDER

NCT07431853 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07431853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07431853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MRNA VACCINES AGAINST INFLUENZA IN ADULTS 18 YEARS OF AGE AND OLDER
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Recruiting
Start date
February 23, 2026
Completion date
June 22, 2027
Enrollment
770 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adults